There is considerable confusion as to how to monitor serum aminoglycos
ide levels when using once-daily dosing. At least five methods are in
use in Australia. We prospectively assessed 100 consecutive once-daily
courses of gentamicin or tobramycin, during which 120 pre-dose and 21
3 sets of immediate post-dose and six hour post-dose levels were taken
. By using the six hour post-dose level we were able to compare dosage
recommendations made using methods known as ALADDIN, DOSECALC and the
Australian Antibiotic Guidelines nomogram (AAGN). There were statisti
cally significant differences in the doses recommended by each method.
When comparing each of the three methods, at least 25% of dosage reco
mmendations differed by more than 80 mg per dose. Although we have not
been able to determine the clinical significance of these differences
, we are concerned that methods used in dosage adjustment of aminoglyc
osides differ so widely in their recommendations. Presumably the ALADD
IN method, which utilises two post-dose levels to determine an area un
der aminoglycoside concentration-time curve, gives more accurate pharm
acokinetic information than methods which rely on a single level, Comp
arative cost-effectiveness studies of different methods, although in p
ractice difficult to perform, should be undertaken to resolve the opti
mal management of patients receiving aminoglycosides once-daily.